This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pricey Stryker Needs a Deal to Spur Healthy Growth

NEW YORK (TheStreet) -- Medical device giant Stryker (SYK - Get Report) has rewarded investors with year-to-date gains of close to 12%. On its own, that's not a breathtaking number. But when compared to the 7% gain of the medical devices sector, according to Morningstar, it's tough to complain.

It's also tough to argue against how expensive these shares have gotten. Currently, they trade around $83.50.

This now pushes Stryker's price to price-to-earnings ratio past 41. That's 13 points higher than the industry average P/E of 28, according to Yahoo! Finance.

Read More: Warren Buffett's Top 10 Dividend Stocks

Investors can have both St. Jude Medical (STJ) and Medtronic (MDT) at much cheaper multiples of 25 and 21, respectively. St. Jude and Medtronic both outperform Stryker in gross margin and operating margin.

While the company has done a decent job addressing a wider range of markets within medical technology, the company reconstructive business continues to struggle, growing just 2.5% in the most recent quarter and trailing the likes of Johnson & Johnson (JNJ) , up 3%, and Biomet, which reported 4% in its most recent report before its pending acquisition.

Johnson & Johnson trades at a P/E that is 22 points lower and pays a 2.80% dividend compared to a 1.50% yield for Stryker. Even if we were to use the "investors are paying for growth" argument, Stryker would still be at a deficit to Johnson & Johnson, which is growing a 9% rate compared to 7% for Stryker.

So where's the value?

At a P/E that almost doubles the industry rate, Stryker should -- at least -- post double-digit revenue growth. To that end, it makes sense for Stryker to seek growth through a merger or an outright acquisition. It's one of the ways that companies with tons of cash but short on growth can have instant access new revenue and markets that would have taken years to build.

Read More: Warren Buffett's Top 10 Dividend Stocks

Medtronic's $42.9 billion deal for Covidien (COV) is one of several recent examples of med-tech M&A that has occurred as companies look to grow and, in some cases, diversify their offerings. Zimmer Holdings (ZMH) wasted no time buying orthopedic device maker Biomet for $13 billion.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
SYK $90.08 -3.10%
AAPL $126.87 0.36%
FB $80.01 -1.50%
GOOG $567.61 -1.30%
TSLA $194.26 -3.20%

Markets

DOW 17,856.78 -278.94 -1.54%
S&P 500 2,071.26 -29.78 -1.42%
NASDAQ 4,927.37 -55.4390 -1.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs